Blog category
Explore our comprehensive blog category on Good Distribution Practice (GDP), a standard ensuring products are consistently distributed and controlled according to quality standards. Dive into insightful industry updates, and best practices to uphold the highest level of quality assurance in pharmaceutical distribution processes.
The sneaky thing about heat is that it never feels like what it's doing to you. You feel a bit tired, a bit done with the day. You don't feel the extra mistakes. But they're there.
Jaap Koster
CEO / Senior GxP Consultant
The EMA has opened a pilot project assessing pharmaceutical quality system effectiveness at manufacturing sites, with inspections running through March 2027. The specific focus: whether your change control process act...
Jaap Koster
CEO / Senior GxP Consultant
In this post, we discuss five FDA topics from 2026 that are relevant (particularly) to QA and regulatory affairs in the US market.
Jaap Koster
CEO / Senior GxP Consultant
A supervisor who understands why a cleaning validation protocol exists will explain it differently to their team than one who just knows it's required. That shows up six months later as fewer repeat deviations. A QA o...
Jaap Koster
CEO / Senior GxP Consultant
For over 35 years, PCS Academy has been training professionals in the pharmaceutical industry. What started in 1991 has grown into a training programme that has educated more than 10,000 GxP professionals — with an av...
Jaap Koster
CEO / Senior GxP Consultant
In GMP environments, the concept of Quality by Design (QbD) is usually discussed in the context of product and process development. Guidance documents consistently emphasize the importance of properly designed premise...
Jaap Koster
CEO / Senior GxP Consultant
he rules that govern the manufacture, import and distribution (a.o.) of medicine consist of a relationship between binding EU legislation, practical guidance, and national (“local”) medicines law that actually powers...
Jaap Koster
CEO / Senior GxP Consultant
“You can’t call it a planned deviation. That’s an oxymoron.” The phrase is usually followed by a name-drop. An inspector said it. A consultant insisted on it. A colleague heard it in an audit debrief. Someone “high up...
Jaap Koster
CEO / Senior GxP Consultant
ALCOA++ is often encountered at the most inconvenient times: during an investigation, audit, or meeting when the question pops up that seems to be the simplest of all: “Who did this, and when?”
Jaap Koster
CEO / Senior GxP Consultant
Too often we find ourselves in discussions with QA teams. The topics are often simple, for example: the standards of manufacturing science—common in any serious manufacturing environment outside pharma—also apply to p...
Jaap Koster
CEO / Senior GxP Consultant
The consultation follows several COVID-19 legal flexibilities in the Human Medicines Regulations 2012 (HMRs) that helped deliver vaccination programmes at scale, and some of those provisions are time-limited and due t...
Jaap Koster
CEO / Senior GxP Consultant
Increasingly, more Dutch transport companies transport medicinal products and want to have a GDP certificate to reassure their customers that they have implemented measures to safeguard quality and safety.
Jaap Koster
CEO / Senior GxP Consultant
For manufacturers and distributors of medicinal products, this is more relevant than it may seem. The document more clearly defines who drafts, who reviews, how broadly changes are scoped, how comments are handled, an...
Jaap Koster
CEO / Senior GxP Consultant
The U.S. FDA published the final version of a Guidance for Industry on conducting remote regulatory assessments in June of 2025. Remote Regulatory Assessments (or in short: RRA's) were utilized during the COVID-19 pan...
Jaap Koster
CEO / Senior GxP Consultant
During recent MES/IT vendor demos for a “paper‑less” pharmaceutical factory, something stood out: No one mapped or discussed data‑flow and data‑risk end‑to‑end, despite years of regulatory focus on data governance. Ev...
Jaap Koster
CEO / Senior GxP Consultant
Ignoring pests just because you haven't visibly noticed them yet is certainly not a strategy—especially when compliance and product safety are on the line.
Jaap Koster
CEO / Senior GxP Consultant
People want a neat definition, a tidy checklist, or a set of metrics to measure quality. But when you peel back the layers, it becomes clear that “Quality Culture” is more of a broad vision than a well-defined endpoint.
Jaap Koster
CEO / Senior GxP Consultant
This blog post addresses 10 common misconceptions in implementing Good Distribution Practice (GDP) within the pharmaceutical supply chain.
Jaap Koster
CEO / Senior GxP Consultant
The Effort Paradox serves as a reminder that knowing isn't the same as doing. In the pharmaceutical industry, where the stakes are high, overcoming this paradox is essential.
Jaap Koster
CEO / Senior GxP Consultant
Navigating the complex landscape of obtaining a Wholesale Distribution Authorization (WDA) license is no easy feat, especially for startups. However, cutting corners and attempting to "hack" your way into compliance c...
Jaap Koster
CEO / Senior GxP Consultant
Download our training programme for 2026 by clicking this link
We use cookies to improve your experience, analyse website usage, and show you relevant information. By accepting all cookies, you help us improve the website. View our privacy statement.
Necessary
Always active. Required for the website to function properly.
Statistics
Helps us improve the website through anonymous statistics.
Marketing
For third-party marketing and tracking cookies.